Flagship explainer
What drives Celldex Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$259M | FY2025 |
| |
| Income before tax | −$259M | FY2025 |
|
| Operating income | −$287M | FY2025 |
|
| $1.5M | FY2025 |
| |
| Ending assets | $583M | FY2025 |
|
| Beginning assets | $792M | FY2024 |
|
| $527M | FY2025 |
| |
| $747M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001104659-26-019652